Company: TXG
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0001628280-25-050332
Chunk: 20

Company: 10x Genomics, Inc.
Filing Date: 2025-11-07
Form: 10-Q
Item: Part I, Item 1
Chunk 20
---
 2025, the UPC found that Curio directly infringes one of the patent’s claims and issued a permanent injunction ordering Curio to cease and desist from selling the Seeker products in Germany, France and Sweden.IlluminaIn October 2025, the Company filed two lawsuits against Illumina, Inc. (“Illumina”) in the United States District Court for the District of Delaware. In the first suit, the Company alleges Illumina’s announced spatial technology program infringe U.S. Patent Nos. 11,008,607, 11.549,138, 12,234,505 and 12,297,487 (collectively, the “Asserted Spatial Patents”). In the second suit, the Company alleges Illumina’s single cell kits and workflow infringe U.S. Patent Nos. 11,692,214, 11,932,902, 12,275,993, 12,305,239 and 12,416,192 (collectively, the “Asserted Single Cell Patents”). No case schedule has been set.

7.    Capital Stock

As of September 30, 2025, the number of shares of Class A common stock and Class B common stock issued and outstanding were 116,460,674 and 10,078,872, respectively.The following table represents the number of shares of Class B common stock converted to shares of Class A common stock upon the election of the holders of such shares during the periods:

16

Table of Contents10x Genomics, Inc.Notes to Unaudited Condensed Consolidated Financial Statements

Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024Class B common stock converted to Class A common stock — — 3,977,961 — 

 8.    Equity Incentive Plans

Stock-based CompensationThe Company recorded stock-based compensation cost for the periods presented as follows (in thousands):Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024Cost of revenue$2,011 $2,169 $6,481 $6,127 Research and development11,318 15,978 38,037 50,728 Selling, general and administrative11,935 15,763 39,067 51,354 Total stock-based compensation expense$25,264 $33,910 $83,585 $108